1/14
08:49 am
rdy
Dr. Reddy’s Announces the First-to-Market Launch of Olopatadine Hydrochloride Ophthalmic Solution USP, 0.7% (OTC), the Generic Equivalent of Extra-Strength Pataday® Once Daily Relief, in the U.S.
Low
Report
Dr. Reddy’s Announces the First-to-Market Launch of Olopatadine Hydrochloride Ophthalmic Solution USP, 0.7% (OTC), the Generic Equivalent of Extra-Strength Pataday® Once Daily Relief, in the U.S.
12/2
08:00 am
rdy
Aurigene Oncology Limited Announces Encouraging Initial Data From 1st Two Cohorts of Phase 1 Study of AUR112, an Oral Small Molecule Inhibitor of MALT1, in Relapsed/Refractory Lymphoid Malignancies
Low
Report
Aurigene Oncology Limited Announces Encouraging Initial Data From 1st Two Cohorts of Phase 1 Study of AUR112, an Oral Small Molecule Inhibitor of MALT1, in Relapsed/Refractory Lymphoid Malignancies
11/18
09:51 am
rdy
ValGenesis Wraps Up Global ValConnect Innovation Day Series with Hyderabad Event [Yahoo! Finance]
Low
Report
ValGenesis Wraps Up Global ValConnect Innovation Day Series with Hyderabad Event [Yahoo! Finance]
10/24
06:59 pm
rdy
Dr. Reddy's Laboratories Limited (RDY) Q2 2026 Earnings Call Transcript [Seeking Alpha]
Medium
Report
Dr. Reddy's Laboratories Limited (RDY) Q2 2026 Earnings Call Transcript [Seeking Alpha]
10/24
12:21 pm
rdy
Dr. Reddy's Laboratories (NYSE:RDY) had its "buy (b-)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
Dr. Reddy's Laboratories (NYSE:RDY) had its "buy (b-)" rating reaffirmed by analysts at
Weiss Ratings.
10/22
12:00 pm
rdy
Aurigene Oncology to Showcase Innovative A-PROX Platform at the AACR-NCI-EORTC International Conference 2025
Low
Report
Aurigene Oncology to Showcase Innovative A-PROX Platform at the AACR-NCI-EORTC International Conference 2025